NR3C1 and ovarian carcinoma: Numerous studies have confirmed that NR3C1 can promote tumor proliferation, metastasis and drug resistance by up-regulating ROR-1 or NF-κB in various malignancies, such as triple-negative breast cancer, ovarian cancer, and urothelial cancer [11–14].